#news #biotech Roche pays €70M upfront for Tusk’s preclinical Treg depleter

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Roche pays €70M upfront for Tusk’s preclinical Treg depleter .Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests.

from FierceBiotech: Biotech https://ift.tt/2Qgf773